Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Analysis of Gender Equity in Leadership of Physician-Focused Medical Specialty Societies, 2008-2017.

Silver JK, Ghalib R, Poorman JA, Al-Assi D, Parangi S, Bhargava H, Shillcutt SK.

JAMA Intern Med. 2019 Jan 7. doi: 10.1001/jamainternmed.2018.5303. [Epub ahead of print] No abstract available.

PMID:
30615072
2.

Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.

Gunda V, Gigliotti B, Ashry T, Ndishabandi D, McCarthy M, Zhou Z, Amin S, Lee KE, Stork T, Wirth L, Freeman GJ, Alessandrini A, Parangi S.

Int J Cancer. 2019 May 1;144(9):2266-2278. doi: 10.1002/ijc.32041. Epub 2019 Jan 24.

PMID:
30515783
3.

Diversity and inclusion in a surgical society: A longitudinal investigation.

Kuo LE, Parangi S, Cho NL.

Surgery. 2019 Apr;165(4):808-813. doi: 10.1016/j.surg.2018.10.027. Epub 2018 Dec 1.

PMID:
30509749
4.

Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.

Boufraqech M, Patel D, Nilubol N, Powers A, King T, Shell J, Lack J, Zhang L, Gara SK, Gunda V, Klubo-Gwiezdzinska J, Kumar S, Fagin J, Knauf J, Parangi S, Venzon D, Quezado M, Kebebew E.

Thyroid. 2019 Jan;29(1):79-92. doi: 10.1089/thy.2018.0424. Epub 2018 Dec 28.

PMID:
30398411
5.

Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer.

Gunda V, Gigliotti B, Ndishabandi D, Ashry T, McCarthy M, Zhou Z, Amin S, Freeman GJ, Alessandrini A, Parangi S.

Br J Cancer. 2018 Nov;119(10):1223-1232. doi: 10.1038/s41416-018-0296-2. Epub 2018 Oct 17.

PMID:
30327563
6.

Denaturation-Enhanced Droplet Digital PCR for Liquid Biopsies.

Fitarelli-Kiehl M, Yu F, Ashtaputre R, Leong KW, Ladas I, Supplee J, Paweletz C, Mitra D, Schoenfeld JD, Parangi S, Makrigiorgos GM.

Clin Chem. 2018 Dec;64(12):1762-1771. doi: 10.1373/clinchem.2018.293845. Epub 2018 Oct 1.

7.

Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma.

Gopal RK, Kübler K, Calvo SE, Polak P, Livitz D, Rosebrock D, Sadow PM, Campbell B, Donovan SE, Amin S, Gigliotti BJ, Grabarek Z, Hess JM, Stewart C, Braunstein LZ, Arndt PF, Mordecai S, Shih AR, Chaves F, Zhan T, Lubitz CC, Kim J, Iafrate AJ, Wirth L, Parangi S, Leshchiner I, Daniels GH, Mootha VK, Dias-Santagata D, Getz G, McFadden DG.

Cancer Cell. 2018 Aug 13;34(2):242-255.e5. doi: 10.1016/j.ccell.2018.06.013.

PMID:
30107175
8.

Leadership in American Surgery: Women are Rising to the Top.

Pories SE, Turner PL, Greenberg CC, Babu MA, Parangi S.

Ann Surg. 2019 Feb;269(2):199-205. doi: 10.1097/SLA.0000000000002978.

PMID:
30048312
9.

Ensuring Equity, Diversity, and Inclusion in Academic Surgery: An American Surgical Association White Paper.

West MA, Hwang S, Maier RV, Ahuja N, Angelos P, Bass BL, Brasel KJ, Chen H, Davis KA, Eberlein TJ, Fong Y, Greenberg CC, Lillemoe KD, McCarthy MC, Michelassi F, Numann PJ, Parangi S, Reyes JD, Sanfey HA, Stain SC, Weigel RJ, Wren SM.

Ann Surg. 2018 Sep;268(3):403-407. doi: 10.1097/SLA.0000000000002937.

PMID:
30004923
10.

Circulating BRAFV600E Levels Correlate with Treatment in Patients with Thyroid Carcinoma.

Lubitz CC, Zhan T, Gunda V, Amin S, Gigliotti BJ, Fingeret AL, Holm TM, Wachtel H, Sadow PM, Wirth LJ, Sullivan RJ, Panka DJ, Parangi S.

Thyroid. 2018 Mar;28(3):328-339. doi: 10.1089/thy.2017.0322. Epub 2018 Feb 27.

11.

PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.

Rosenbaum MW, Gigliotti BJ, Pai SI, Parangi S, Wachtel H, Mino-Kenudson M, Gunda V, Faquin WC.

Endocr Pathol. 2018 Mar;29(1):59-67. doi: 10.1007/s12022-018-9514-y.

PMID:
29372535
12.

Evaluating the projected surgical impact of reclassifying noninvasive encapsulated follicular variant of papillary thyroid cancer as noninvasive follicular thyroid neoplasm with papillary-like nuclear features.

Mainthia R, Wachtel H, Chen Y, Mort E, Parangi S, Sadow PM, Lubitz CC.

Surgery. 2018 Jan;163(1):60-65. doi: 10.1016/j.surg.2017.04.037. Epub 2017 Nov 13.

13.

Injection of bulking agents for laryngoplasty.

Snyder SK, Angelos P, Carty SE, Doherty GM, Howe JR, Lee JA, Libutti SK, Miller BS, Parangi S, Patel KN, Sippel RC, Sturgeon C, Wang TS, Yip L, Zeiger MA.

Surgery. 2018 Jan;163(1):6-8. doi: 10.1016/j.surg.2017.08.019. Epub 2017 Nov 9. No abstract available.

PMID:
29129367
14.

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.

Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, Sorrentino JA, Bisi JE, Lizotte PH, Merlino AA, Quinn MM, Bufe LE, Yang A, Zhang Y, Zhang H, Gao P, Chen T, Cavanaugh ME, Rode AJ, Haines E, Roberts PJ, Strum JC, Richards WG, Lorch JH, Parangi S, Gunda V, Boland GM, Bueno R, Palakurthi S, Freeman GJ, Ritz J, Haining WN, Sharpless NE, Arthanari H, Shapiro GI, Barbie DA, Gray NS, Wong KK.

Cancer Discov. 2018 Feb;8(2):216-233. doi: 10.1158/2159-8290.CD-17-0915. Epub 2017 Nov 3.

15.

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA.

Cancer Discov. 2018 Feb;8(2):196-215. doi: 10.1158/2159-8290.CD-17-0833. Epub 2017 Nov 3.

16.

Primary lymph node gastrinoma: A single institution experience.

Chen Y, Deshpande V, Ferrone C, Blaszkowsky LS, Parangi S, Warshaw AL, Lillemoe KD, Fernandez-Del Castillo C.

Surgery. 2017 Nov;162(5):1088-1094. doi: 10.1016/j.surg.2017.05.017. Epub 2017 Jul 10.

PMID:
28705492
17.

Where Are the Women? The Underrepresentation of Women Physicians Among Recognition Award Recipients From Medical Specialty Societies.

Silver JK, Slocum CS, Bank AM, Bhatnagar S, Blauwet CA, Poorman JA, Villablanca A, Parangi S.

PM R. 2017 Aug;9(8):804-815. doi: 10.1016/j.pmrj.2017.06.001. Epub 2017 Jun 9.

18.

Strategies for Identifying and Closing the Gender Salary Gap in Surgery.

Sanfey H, Crandall M, Shaughnessy E, Stein SL, Cochran A, Parangi S, Laronga C.

J Am Coll Surg. 2017 Aug;225(2):333-338. doi: 10.1016/j.jamcollsurg.2017.03.018. Epub 2017 Apr 9. Review. No abstract available.

PMID:
28400299
19.

Inhibition of MAPKinase pathway sensitizes thyroid cancer cells to ABT-737 induced apoptosis.

Gunda V, Sarosiek KA, Brauner E, Kim YS, Amin S, Zhou Z, Letai A, Parangi S.

Cancer Lett. 2017 Jun 1;395:1-10. doi: 10.1016/j.canlet.2017.02.028. Epub 2017 Mar 1.

PMID:
28259821
20.

Measurement and Variation in Estimation of Quality of Life Effects of Patients Undergoing Treatment for Papillary Thyroid Carcinoma.

Lubitz CC, De Gregorio L, Fingeret AL, Economopoulos KP, Termezawi D, Hassan M, Parangi S, Stephen AE, Halpern EF, Donelan K, Swan JS.

Thyroid. 2017 Feb;27(2):197-206. doi: 10.1089/thy.2016.0260. Epub 2016 Dec 15.

21.

The Bethesda System for Reporting Thyroid Cytopathology: Proposed Modifications and Updates for the Second Edition from an International Panel.

Pusztaszeri M, Rossi ED, Auger M, Baloch Z, Bishop J, Bongiovanni M, Chandra A, Cochand-Priollet B, Fadda G, Hirokawa M, Hong S, Kakudo K, Krane JF, Nayar R, Parangi S, Schmitt F, Faquin WC.

Acta Cytol. 2016;60(5):399-405. Epub 2016 Oct 21. Review.

22.

Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer.

Liu Y, Gunda V, Zhu X, Xu X, Wu J, Askhatova D, Farokhzad OC, Parangi S, Shi J.

Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7750-5. doi: 10.1073/pnas.1605841113. Epub 2016 Jun 24.

23.

The Truth about Double Adenomas: Incidence, Localization, and Intraoperative Parathyroid Hormone.

De Gregorio L, Lubitz CC, Hodin RA, Gaz RD, Parangi S, Phitayakorn R, Stephen AE.

J Am Coll Surg. 2016 Jun;222(6):1044-52. doi: 10.1016/j.jamcollsurg.2015.12.048. Epub 2016 Jan 13.

PMID:
27234627
24.

Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.

Brauner E, Gunda V, Vanden Borre P, Zurakowski D, Kim YS, Dennett KV, Amin S, Freeman GJ, Parangi S.

Oncotarget. 2016 Mar 29;7(13):17194-211. doi: 10.18632/oncotarget.7839.

25.

Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma.

Lubitz CC, Parangi S, Holm TM, Bernasconi MJ, Schalck AP, Suh H, Economopoulos KP, Gunda V, Donovan SE, Sadow PM, Wirth LJ, Sullivan RJ, Panka DJ.

J Mol Diagn. 2016 Jan;18(1):100-8. doi: 10.1016/j.jmoldx.2015.08.003. Epub 2015 Nov 26.

26.

Editorial: Translaryngeal vocal cord ultrasound: Ready for prime time.

Parangi S.

Surgery. 2016 Jan;159(1):67-9. doi: 10.1016/j.surg.2015.10.014. Epub 2015 Oct 29. No abstract available.

PMID:
26522697
27.

Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines.

Varmeh S, Vanden Borre P, Gunda V, Brauner E, Holm T, Wang Y, Sadreyev RI, Parangi S.

Surgery. 2016 Jan;159(1):152-62. doi: 10.1016/j.surg.2015.06.046. Epub 2015 Oct 9.

28.

Should specific patient clinical characteristics discourage adrenal surgeons from performing laparoscopic transperitoneal adrenalectomy?

Economopoulos KP, Phitayakorn R, Lubitz CC, Sadow PM, Parangi S, Stephen AE, Hodin RA.

Surgery. 2016 Jan;159(1):240-8. doi: 10.1016/j.surg.2015.07.045. Epub 2015 Oct 9.

PMID:
26453136
29.

Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules.

Brauner E, Holmes BJ, Krane JF, Nishino M, Zurakowski D, Hennessey JV, Faquin WC, Parangi S.

Thyroid. 2015 Jul;25(7):789-96. doi: 10.1089/thy.2015.0049. Epub 2015 Jun 4.

PMID:
25962906
30.

Case records of the Massachusetts General Hospital. Case 10-2015. A 15-year-old girl with Graves’ disease and psychotic symptoms.

Hazen EP, Sherry NA, Parangi S, Rabito CA, Sadow PM.

N Engl J Med. 2015 Mar 26;372(13):1250-8. doi: 10.1056/NEJMcpc1314239. No abstract available. Erratum in: N Engl J Med. 2015 Jun 4;372(23):2274. N Engl J Med. 2015 Jun 4;372(23):2274. Dosage error in article text..

PMID:
25806918
31.

Pediatric thyroidectomy in a high volume thyroid surgery center: Risk factors for postoperative hypocalcemia.

Chen Y, Masiakos PT, Gaz RD, Hodin RA, Parangi S, Randolph GW, Sadow PM, Stephen AE.

J Pediatr Surg. 2015 Aug;50(8):1316-9. doi: 10.1016/j.jpedsurg.2014.10.056. Epub 2014 Nov 5.

PMID:
25783304
32.
33.

The role of genetic markers in the evaluation and management of thyroid nodules.

Parangi S, Suh H.

Surg Clin North Am. 2014 Jun;94(3):515-28. doi: 10.1016/j.suc.2014.03.001. Epub 2014 Apr 24. Review.

PMID:
24857574
34.

A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.

Gunda V, Frederick DT, Bernasconi MJ, Wargo JA, Parangi S.

Thyroid. 2014 Aug;24(8):1241-50. doi: 10.1089/thy.2013.0680. Epub 2014 Jun 30.

35.

AACE/ACE disease state commentary: molecular diagnostic testing of thyroid nodules with indeterminate cytopathology.

Bernet V, Hupart KH, Parangi S, Woeber KA.

Endocr Pract. 2014 Apr;20(4):360-3. doi: 10.4158/EP14066.PS.

PMID:
24727662
36.

Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways.

Gunda V, Bucur O, Varnau J, Vanden Borre P, Bernasconi MJ, Khosravi-Far R, Parangi S.

Cell Death Dis. 2014 Mar 6;5:e1104. doi: 10.1038/cddis.2014.78.

37.

The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma.

Vanden Borre P, McFadden DG, Gunda V, Sadow PM, Varmeh S, Bernasconi M, Jacks T, Parangi S.

Thyroid. 2014 Apr;24(4):705-14. doi: 10.1089/thy.2013.0483. Epub 2014 Jan 24.

38.

Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer.

Gunda V, Cogdill AP, Bernasconi MJ, Wargo JA, Parangi S.

Surgery. 2013 Dec;154(6):1456-62; discussion 1462. doi: 10.1016/j.surg.2013.07.009.

39.

Surgery for Graves' disease: a 25-year perspective.

Phitayakorn R, Morales-Garcia D, Wanderer J, Lubitz CC, Gaz RD, Stephen AE, Ehrenfeld JM, Daniels GH, Hodin RA, Parangi S.

Am J Surg. 2013 Nov;206(5):669-73. doi: 10.1016/j.amjsurg.2013.07.005. Epub 2013 Sep 4.

PMID:
24011567
40.

The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1.

Qin L, Zhao D, Xu J, Ren X, Terwilliger EF, Parangi S, Lawler J, Dvorak HF, Zeng H.

Blood. 2013 Mar 14;121(11):2154-64. doi: 10.1182/blood-2012-07-443903. Epub 2013 Jan 11.

41.

BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence.

Prescott JD, Sadow PM, Hodin RA, Le LP, Gaz RD, Randolph GW, Stephen AE, Parangi S, Daniels GH, Lubitz CC.

Surgery. 2012 Dec;152(6):984-90. doi: 10.1016/j.surg.2012.08.039.

42.

Management of thyroid nodules with atypical cytology on fine-needle aspiration biopsy.

Nagarkatti SS, Faquin WC, Lubitz CC, Garcia DM, Barbesino G, Ross DS, Hodin RA, Daniels GH, Parangi S.

Ann Surg Oncol. 2013 Jan;20(1):60-5. doi: 10.1245/s10434-012-2601-2. Epub 2012 Sep 1.

43.

Diagnostic yield of nondiagnostic thyroid nodules is not altered by timing of repeat biopsy.

Lubitz CC, Nagarkatti SS, Faquin WC, Samir AE, Hassan MC, Barbesino G, Ross DS, Randolph GW, Gaz RD, Stephen AE, Hodin RA, Daniels GH, Parangi S.

Thyroid. 2012 Jun;22(6):590-4. doi: 10.1089/thy.2011.0442.

44.

Thyroid lobe ablation with radioactive iodine as an alternative to completion thyroidectomy after hemithyroidectomy in patients with follicular thyroid carcinoma: long-term follow-up.

Barbesino G, Goldfarb M, Parangi S, Yang J, Ross DS, Daniels GH.

Thyroid. 2012 Apr;22(4):369-76. doi: 10.1089/thy.2011.0198. Epub 2012 Mar 2.

45.

Ultrasound-guided percutaneous thyroid nodule core biopsy: clinical utility in patients with prior nondiagnostic fine-needle aspirate.

Samir AE, Vij A, Seale MK, Desai G, Halpern E, Faquin WC, Parangi S, Hahn PF, Daniels GH.

Thyroid. 2012 May;22(5):461-7. doi: 10.1089/thy.2011.0061. Epub 2012 Feb 3.

46.

Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.

Nehs MA, Nucera C, Nagarkatti SS, Sadow PM, Morales-Garcia D, Hodin RA, Parangi S.

Endocrinology. 2012 Feb;153(2):985-94. doi: 10.1210/en.2011-1519. Epub 2011 Dec 27.

47.

Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma.

Yip DT, Hassan M, Pazaitou-Panayiotou K, Ruan DT, Gawande AA, Gaz RD, Moore FD Jr, Hodin RA, Stephen AE, Sadow PM, Daniels GH, Randolph GW, Parangi S, Lubitz CC.

Surgery. 2011 Dec;150(6):1168-77. doi: 10.1016/j.surg.2011.09.043.

48.

Bilaterality in papillary thyroid carcinoma: does it influence prognosis?

Prescott JD, Parangi S.

Ann Surg Oncol. 2012 Jan;19(1):1-2. doi: 10.1245/s10434-011-2098-0. No abstract available.

49.

Medical and surgical risks in thyroid surgery: lessons from the NSQIP.

Goldfarb M, Perry Z, A Hodin R, Parangi S.

Ann Surg Oncol. 2011 Dec;18(13):3551-8. doi: 10.1245/s10434-011-1938-2. Epub 2011 Jul 20.

PMID:
21769463
50.

BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.

Nucera C, Lawler J, Parangi S.

Cancer Res. 2011 Apr 1;71(7):2417-22. doi: 10.1158/0008-5472.CAN-10-3844. Epub 2011 Mar 29. Review.

Supplemental Content

Loading ...
Support Center